CAT-2200 is a human monoclonal antibody (IgG1/lambda) targeting Interleukin-17A (IL-17A/CTLA-8). IL-17A is a critical pro-inflammatory cytokine produced by Th17 cells, playing a central role in the pathology of autoimmune diseases such as psoriasis, rheumatoid arthritis, and multiple sclerosis. CAT-2200 specifically binds to the IL-17A homodimer, blocking its interaction with cell surface receptors (IL-17RA/IL-17RC), thereby effectively neutralizing the biological activity of IL-17A. Studies demonstrate that CAT-2200 significantly inhibits the IL-17A-induced release of downstream inflammatory mediators (e.g., IL-6, IL-8, and GRO-alpha). This antibody is frequently used as a tool antibody or positive control for researching the IL-17A signaling pathway and its role in inflammatory responses.
Target:
Interleukin
T9901A-1447
* VAT and and shipping costs not included. Errors and price changes excepted
